









Amended Claims

1. (currently amended) A compound of [[the]] formula (I):



or a pharmaceutically acceptable salt or ester thereof, wherein:



G is selected from the group consisting of:



wherein

Q is NH or O; [and]

Q' is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, and phenyl-C<sub>1</sub>-C<sub>4</sub>-alkyl;



wherein

R' and R'' are independently H or C<sub>1</sub>-C<sub>4</sub>-alkyl;

02/18/2004 MAHMED1 00000140 09924732

01-FC-1252 420.00-0P  
02/18/2004 MAHMED1 00000140 09924732  
02-FC-1202 186.00-0P

B is C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>2</sub>-C<sub>4</sub> alkenyl;


A is selected from the group consisting of CH<sub>2</sub>, O, S(O)<sub>p</sub> ~~wherein p is zero, 1 or 2~~, NH, ~~a group~~ CON(R''), and [[or]] N(R'')CO<sub>2</sub> ~~wherein~~

p is zero, 1, or 2;

R'' is hydrogen or CH<sub>3</sub>;

R<sub>1</sub> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, halogen, and CF<sub>3</sub>;

X is [[()] C=O [()]<sub>m</sub> wherein m is 0 or 1] or a bond, except that X is C=O when G is:



R<sub>2</sub> is selected from the group consisting of:

H; [(),]

C<sub>1</sub>-C<sub>4</sub> alkyl; [(),]

C<sub>3</sub>-C<sub>7</sub> cycloalkyl; [(),]

C<sub>1</sub>-C<sub>4</sub>-alkylcycloalkyl;

aryl ~~unsubstituted or~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; and

a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, and isoxazolyl, wherein: C<sub>5</sub>-C<sub>7</sub> monocyclic heteroaryl ring having one to three heteroatoms selected from O, S, and N, unsubstituted or

any such heteroaryl is optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;


Y is (CH<sub>2</sub>)<sub>n</sub>; ~~wherein~~

n is 1 or 2; and

R is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub>


**Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004**

alkynyl, aryl, and [[or]] aryl-C<sub>1</sub>-C<sub>4</sub> alkyl. With the proviso that m cannot be 0 when G is:





2. (currently amended) A compound, salt, or ester according to claim 1, wherein:

G is selected from the group consisting of:



wherein Q is NH or O and Q' is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, and phenyl-C<sub>1</sub>-C<sub>4</sub>-alkyl;



wherein R' is independently H or C<sub>1</sub>-C<sub>4</sub>-alkyl;

B is  $(\text{CH}_2)_q$ ; wherein


$q$  is 2, 3, or 4; and

$R_2$  is: [[a]]


phenyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy; aralkyl; or

pyridine **ring unsubstituted or** optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy.

~~With the proviso that m can not be 0 when C is:~~



3. (currently amended) A compound, salt, or ester according to claim 1, wherein:  
G is selected from the group consisting of:



B is (CH<sub>2</sub>)<sub>q</sub>; ~~wherein~~  
q is 2, 3, or 4; and  
R<sub>2</sub> is: [(a)]

a phenyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; or

pyridine **ring unsubstituted or** optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy.

4. (currently amended) The compound, salt, or ester as recited in claim 1, wherein the compound is selected from the group consisting of:

(4-phenyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-methyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, ;

~~(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

(4-cyclopropylmethyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

(4-benzyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[[3-(2-pyridinylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[[5-(2-pyridinylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[[3-(2-pyridinylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[[5-(2-pyridinylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6-[[2-(2-pyridinylamino)ethylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[[3-(2-pyridinylamino)propylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;


[4-phenyl-6-[(4-(2-pyridinylamino)butylamino)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[(2-(1H-imidazol-2-ylamino)ethylamino)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[(3-(1H-imidazol-2-ylamino)propylamino)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;








[4-phenyl-6-[(4-(1H-imidazol-2-ylamino)butylamino)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

5. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a [[the]] compound of [[the]] formula (I):



or a pharmaceutically acceptable salt or ester thereof, wherein:


G is selected from the group consisting of:



wherein

Q is NH or O; [[and]]

Q' is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, and phenyl-C<sub>1</sub>-C<sub>4</sub> alkyl;



**wherein**

R' and R'' are independently H or C<sub>1</sub>-C<sub>4</sub>-alkyl;

B is C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>2</sub>-C<sub>4</sub> alkenyl;

A is selected from the group consisting of CH<sub>2</sub>, O, S(O)<sub>p</sub> **wherein p is zero, 1 or 2**, NH,


**a group CON(R''), and [[or]] N(R'')CO;** **wherein**

R'' is hydrogen or CH<sub>3</sub>;

**p is zero, 1 or 2;**

R<sub>1</sub> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, halogen, and CF<sub>3</sub>;

X is [[() C=O ()]<sub>m</sub> **wherein m is 0 or 1]] or a bond, except that X is C=O when G is:**



R<sub>2</sub> is selected from the group consisting of:

H; [(),]

C<sub>1</sub>-C<sub>4</sub> alkyl; [(),]

C<sub>3</sub>-C<sub>7</sub> cycloalkyl; [(),]

C<sub>1</sub>-C<sub>4</sub>-alkylcycloalkyl;

aryl **unsubstituted or** optionally substituted by one to three substituents

independently selected from **the group consisting of** halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; and

**a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,**


oxazolyl, and isoxazolyl, wherein: C<sub>5</sub>-C<sub>7</sub>-monocyclic heteroaryl ring having one to three heteroatoms selected from O, S, and N, unsubstituted or any such heteroaryl is optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

Y is (CH<sub>2</sub>)<sub>n</sub>; wherein

n is 1 or 2; and

R is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, aryl, and [(or)] aryl-C<sub>1</sub>-C<sub>4</sub> alkyl.








~~With the proviso that m can not be 0 when G is:~~





~~wherein Q' is H and Q is O and X is (C=O)<sub>m</sub>.~~

6. (currently amended) A pharmaceutical composition of claim 5, wherein:

G is selected from the group consisting of:



~~wherein Q is NH or O and Q' is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, and phenyl-C<sub>1</sub>-C<sub>4</sub>alkyl;~~



~~wherein R' is independently H or C<sub>1</sub>-C<sub>4</sub>-alkyl;~~

B is (CH<sub>2</sub>)<sub>q</sub>; ~~wherein~~

q is 2, 3, or 4; and


R<sub>2</sub> is: [[a]]

phenyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; or


pyridine ~~ring unsubstituted~~ or optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy.

~~With the proviso that m can not be 0 when G is:~~



7. (currently amended) A pharmaceutical composition of claim 5, wherein:

G is selected from the group consisting of:



B is  $(CH_2)_q$ ; **wherein**

q is 2, 3, or 4; **and**

R<sub>2</sub> is: [[a]]

phenyl **optionally substituted** by one to three substituents independently selected from **the group consisting of** halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; or

pyridine **ring-unsubstituted or** optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy.

8. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, **prodrug** or ester thereof as recited in claim 5, wherein the compound is selected from the group consisting of:

(4-phenyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

2-yl)acetic acid;

(4-methyl-6-{{[3-(1H-imidazol-2-ylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{{[4-(1H-imidazol-2-ylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-methyl-6-{{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid ;

~~(4-cyclopropylmethyl-6-{{[3-(2-pyridinylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{{[4-(2-pyridinylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{{[5-(2-pyridinylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{{[3-(1H-imidazol-2-ylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{{[4-(1H-imidazol-2-ylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclopropylmethyl-6-{{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{{[3-(2-pyridinylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{{[4-(2-pyridinylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{{[5-(2-pyridinylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{{[3-(1H-imidazol-2-ylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{{[4-(1H-imidazol-2-ylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~

~~(4-cyclohexylmethyl-6-{{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}}-3,4-dihydro-~~

~~2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzoyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzoyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzoyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzoyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzoyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-benzoyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-neicotinoyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-neicotinoyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;~~  
~~(4-neicotinoyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-~~

**benzoxazin-2-yl)acetic acid;**

**(4-nicotinoyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-nicotinoyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-nicotinoyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**{4-phenyl-6-[(2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;**

**{4-phenyl-6-[(3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;**

**{4-phenyl-6-[(4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;**


**{4-phenyl-6-[(2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;**

**{4-phenyl-6-[(3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;**

**{4-phenyl-6-[(4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.**








9. (currently amended) A method for treating a mammal having a condition treatable by inhibiting mediated by the  $\alpha_v\beta_3$  integrin, wherein: in a mammal in need of such treatment, including a human, comprising

the method comprises administering to said mammal an effective  $\alpha_v\beta_3$  inhibiting amount of a compound of [[the]] formula (I) or a pharmaceutically acceptable salt or ester thereof:



**wherein:**



G is selected from the group consisting of:



**wherein**

Q is NH or O; **[and]**

Q' is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, and phenyl-C<sub>1</sub>-C<sub>4</sub>-alkyl;



**wherein**

R' and R'' are independently H or C<sub>1</sub>-C<sub>4</sub>-alkyl;

B is C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>2</sub>-C<sub>4</sub> alkenyl;

A is selected from the group consisting of CH<sub>2</sub>, O, S(O)<sub>p</sub> **wherein p is zero, 1 or 2**, NH,

**a group CON(R''), and [or] N(R'')CO;** **wherein**


**p is zero, 1, or 2;**

R'' is hydrogen or CH<sub>3</sub>;

R<sub>1</sub> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, OH, halogen,

and CF<sub>3</sub>;

X is [|(] C=O [)]<sub>m</sub> wherein m is 0 or 1] and a bond, except that X is C=O when G is:



R<sub>2</sub> is selected from the group consisting of:

H; [,]

C<sub>1</sub>-C<sub>4</sub> alkyl; [,]

C<sub>3</sub>-C<sub>7</sub> cycloalkyl; [,]

C<sub>1</sub>-C<sub>4</sub>-alkylcycloalkyl;

aryl unsubstituted or optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; and


a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, and isoxazolyl, wherein: C<sub>5</sub>-C<sub>7</sub>-monocyclic heteroaryl ring having one to three heteroatoms selected from O, S, and N, unsubstituted or

any such heteroaryl is optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

Y is (CH<sub>2</sub>)<sub>n</sub>; wherein








n is 1 or 2; and

R is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, aryl, and [or] aryl-C<sub>1</sub>-C<sub>4</sub> alkyl. ~~With the proviso that m cannot be 0 when G is:~~






10. (currently amended) The method of claim 9, wherein:

G is selected from the group consisting of:



~~wherein Q is NH or O and Q' is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, and phenyl-C<sub>1</sub>-C<sub>4</sub> alkyl;~~



~~wherein R' is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;~~

B is (CH<sub>2</sub>)<sub>q</sub>; ~~wherein~~

q is 2, 3, or 4; and


R<sub>2</sub> is: [a]

phenyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; or


pyridine ring unsubstituted or optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy.

~~With the proviso that m can not be 0 when G is:~~



11. (currently amended) The method of claim 9, wherein:

G is selected from the group consisting of:



B is  $(CH_2)_q$ , ~~wherein~~

$q$  is 2, 3, or 4; and

R<sub>2</sub> is: [[a]]

phenyl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy;

aralkyl; or

pyridine ~~ring unsubstituted or~~ optionally substituted by one to three substituents independently selected from the group consisting of halogen, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, and C<sub>1</sub>-C<sub>4</sub> alkoxy.

12. (currently amended) The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-phenyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-

benzoxazin-2-yl)acetic acid;

(4-phenyl-6- {[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6- {[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6- {[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6- {[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6- {[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6- {[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6- {[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; **and**

(4-methyl-6- {[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid ;

**(4-cyclopropylmethyl-6- {[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-cyclopropylmethyl-6- {[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-cyclopropylmethyl-6- {[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-cyclopropylmethyl-6- {[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-cyclopropylmethyl-6- {[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-cyclopropylmethyl-6- {[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

**(4-cyclohexylmethyl-6- {[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;**

(4-cyclohexylmethyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

(4-benzoyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[(3-(2-pyridinylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[(4-(2-pyridinylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[(5-(2-pyridinylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[(3-(1H-imidazol-2-ylamino)propanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[(4-(1H-imidazol-2-ylamino)butanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-[(5-(1H-imidazol-2-ylamino)pentanoyl]amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6-[(2-(2-pyridinylamino)ethylamino]carbonyl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[(3-(2-pyridinylamino)propylamino]carbonyl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[(4-(2-pyridinylamino)butylamino]carbonyl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[(2-(1H-imidazol-2-ylamino)ethylamino]carbonyl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[(3-(1H-imidazol-2-ylamino)propylamino]carbonyl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[(4-(1H-imidazol-2-ylamino)butylamino]carbonyl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.

13. (currently amended) The method according to claim 9, wherein the condition

treated is bone resorption, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, neoplasia (solid tumor growth), angiogenesis ~~including tumor angiogenesis~~, diabetic retinopathy, arthritis, psoriasis, [[and]] periodontal disease, or smooth muscle cell migration ~~including restenosis~~.

14. (currently amended) The method according to claim 12, wherein the condition treated is bone resorption, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, neoplasia (solid tumor growth), angiogenesis ~~including tumor angiogenesis~~, diabetic retinopathy, arthritis, psoriasis, [[and]] periodontal disease, or smooth muscle cell migration ~~including restenosis~~.

15. (currently amended) A ~~combined~~ method of treatment of cancer or of controlling the growth of a neoplasm in a mammal suffering from cancer, ~~including a human~~, said method comprising administering simultaneous, separately, or sequentially the following agents in amounts and close enough together in time sufficient to produce a therapeutically useful effect: [l,]

- 1) a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt [[salts]] thereof; and
- 2) an additional antitumor agent ;~~in amounts and close enough together in time sufficient to produce a therapeutically useful effect.~~

16. (original) The method according to claim 15, wherein the additional antitumor agent is selected from the group consisting of an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

17. (currently amended) A combination pack product containing a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and an effective antineoplastic amount of additional antitumor agent as a combined preparation for simultaneous, separate, or sequential use in anti-cancer therapy.

18. (currently amended) The combination pack product according to claim 17, wherein the additional antitumor agent is selected from the group consisting of an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite, and an antineoplastic topoisomerase I inhibitor.

19. (new) The compound as recited in claim-1, wherein the compound is selected from the group consisting of:

(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

1,4-benzoxazin-2-yl)acetic acid; and

(4-cyclohexylmethyl-6-{{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

20. (new) The compound as recited in claim 1, wherein the compound is selected from the group consisting of:

(4-benzyl-6-{{[3-(2-pyridinylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{{[4-(2-pyridinylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{{[5-(2-pyridinylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{{[3-(1H-imidazol-2-ylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{{[4-(1H-imidazol-2-ylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{{[3-(2-pyridinylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{{[4-(2-pyridinylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{{[5-(2-pyridinylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{{[3-(1H-imidazol-2-ylamino)propanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{{[4-(1H-imidazol-2-ylamino)butanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-benzoyl-6-{{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

21. (new) The compound as recited in claim 1, wherein the compound is selected from the group consisting of:

(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid; and

[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.

22. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or ester thereof as recited in claim 5,

wherein the compound is selected from the group consisting of:

(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

23. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or ester thereof as recited in claim 5, wherein the compound is selected from the group consisting of:

(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

2-yl)acetic acid;

(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

24. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or ester thereof as recited in claim 5, wherein the compound is selected from the group consisting of:

(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;  
(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6-{[2-(2-pyridinylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid; and

[4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.

25. (new) The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-cyclopropylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-cyclohexylmethyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

26. (new) The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-benzyl-6-{[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

(4-benzyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid; and

(4-benzoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

27. (**new**) The method according to claim 9, wherein the compound is selected from the group consisting of:

(4-nicotinoyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-nicotinoyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

[4-phenyl-6- {[2-(2-pyridinylamino)ethylamino]carbonyl} -3,4-dihydro-2H-1,4-

Amendment C  
U.S. Appl. 09/924,732  
February 12, 2004

benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{3-(2-pyridinylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{4-(2-pyridinylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{2-(1H-imidazol-2-ylamino)ethylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{3-(1H-imidazol-2-ylamino)propylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid; and

[4-phenyl-6-{{4-(1H-imidazol-2-ylamino)butylamino]carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.